Maridebart cafraglutide — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 4 sources[1,2,3,4].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | How may GIP enhance the therapeutic efficacy of GLP-1? | Trends in Endocrinology & Metabolism | 2020 |
| 2 | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from… | Molecular Metabolism | 2018 |
| 3 | Tirzepatide once weekly for the treatment of obesity | New England Journal of Medicine | 2022 |
| 4 | ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | ICH Harmonised Tripartite Guideline | 1999 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 10 | MARITIDE-PH2-OBESITY · MARITIDE-PH2-T2D · MARITIDE-PH3 · MARITIDE-PH2-OBESITY-HEPATIC-IMP · MARITIDE-PH2-T2D-REGIONAL-JP · MARITIDE-PH3-RENAL-IMP · MARITIDE-PH2-T2D-BODY-COMP · MARITIDE-PH2-T2D-REGIONAL-CN · MARITIDE-PH3-HEPATIC-IMP · MARITIDE-PH3-BIOMARKER |
| Evidence syntheses | 2 | Maridebart cafraglutide in obesity and overweight in… · Maridebart cafraglutide in obesity and overweight in… |
| Comment periods | 1 | Draft monograph: Maridebart cafraglutide |
| Indication assessments | 2 | Obesity · Type 2 diabetes |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends in Endocrinology & Metabolism 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006 · PMID 32396843
- Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009 · PMID 30473097
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PMID 35658024
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.